Gibbs Wealth Management Sells 12,089 Shares of The Cooper Companies, Inc. $COO

Gibbs Wealth Management cut its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 55.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,783 shares of the medical device company’s stock after selling 12,089 shares during the quarter. Gibbs Wealth Management’s holdings in Cooper Companies were worth $671,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in COO. Vanguard Group Inc. increased its position in Cooper Companies by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 24,254,677 shares of the medical device company’s stock worth $1,725,963,000 after purchasing an additional 421,423 shares in the last quarter. State Street Corp grew its position in Cooper Companies by 1.2% during the 2nd quarter. State Street Corp now owns 8,659,741 shares of the medical device company’s stock worth $616,227,000 after acquiring an additional 104,910 shares during the last quarter. Geode Capital Management LLC raised its position in Cooper Companies by 2.5% in the second quarter. Geode Capital Management LLC now owns 5,205,615 shares of the medical device company’s stock valued at $368,893,000 after purchasing an additional 127,907 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Cooper Companies by 98.8% during the second quarter. Ameriprise Financial Inc. now owns 3,388,413 shares of the medical device company’s stock worth $241,120,000 after purchasing an additional 1,683,561 shares during the last quarter. Finally, Sustainable Growth Advisers LP acquired a new position in shares of Cooper Companies in the second quarter valued at approximately $240,881,000. Institutional investors own 24.39% of the company’s stock.

Analyst Ratings Changes

COO has been the subject of several recent research reports. Robert W. Baird upped their price target on shares of Cooper Companies from $85.00 to $98.00 and gave the company an “outperform” rating in a research report on Friday, December 5th. Citigroup restated a “neutral” rating and set a $88.00 price objective (up from $72.00) on shares of Cooper Companies in a research report on Monday, December 8th. Stifel Nicolaus set a $95.00 target price on shares of Cooper Companies and gave the company a “buy” rating in a research report on Friday, December 5th. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $73.00 price objective on shares of Cooper Companies in a research note on Friday, January 9th. Finally, Weiss Ratings raised shares of Cooper Companies from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, January 12th. Eight analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $90.31.

Cooper Companies Price Performance

Shares of NASDAQ COO opened at $81.29 on Friday. The firm’s 50-day moving average price is $80.24 and its 200-day moving average price is $74.03. The Cooper Companies, Inc. has a 1-year low of $61.78 and a 1-year high of $100.24. The firm has a market capitalization of $15.93 billion, a P/E ratio of 43.24, a P/E/G ratio of 2.32 and a beta of 1.03. The company has a current ratio of 1.89, a quick ratio of 1.13 and a debt-to-equity ratio of 0.30.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Thursday, December 4th. The medical device company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.11 by $0.04. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The company had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period last year, the business posted $1.04 EPS. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Equities research analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Insider Buying and Selling at Cooper Companies

In other Cooper Companies news, Director Lawrence Erik Kurzius bought 2,000 shares of the stock in a transaction that occurred on Wednesday, December 17th. The shares were bought at an average price of $82.50 per share, for a total transaction of $165,000.00. Following the acquisition, the director directly owned 7,777 shares of the company’s stock, valued at approximately $641,602.50. The trade was a 34.62% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Albert G. White III purchased 10,000 shares of the business’s stock in a transaction on Tuesday, December 16th. The shares were bought at an average price of $80.80 per share, with a total value of $808,000.00. Following the purchase, the chief executive officer directly owned 236,151 shares in the company, valued at approximately $19,081,000.80. The trade was a 4.42% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 16,014 shares of company stock worth $1,304,416 in the last ninety days. 1.98% of the stock is currently owned by corporate insiders.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.